US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.37

+0.01270.05%

Post-market: 27.500.1304+0.48%16:10 EDT

Volume:1K

Turnover:32.81K

Market Cap:2.46M

PE:- -

High:27.50

Open:27.40

Low:27.37

Close:27.36

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:3.97

T/O Rate:1.33%

Dividend:0.45

Dividend Rate:1.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

Takeda receives FDA approval of NDA for Mimrylo

Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup

Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative

Simply Wall St.

NeuroThera Labs Hires European IR Firm to Expand Investor Reach

Oppenheimer biotech analysts hold an analyst/industry conference call

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

Becton Dickinson announces STANCE clinical trial enrollment milestone

Natera and Angiex partner in tumor testing using Signatera

Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs

Roche receives FDA approval for companion diagnostic tests for Ziihera

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

Revolution Medicines announces FDA approval of Rasonque in adults

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/NVIB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.3696,"timestamp":1789156800000,"preClose":27.3569,"halted":0,"volume":1193,"hourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"delay":0,"changeRate":0.000464233886149338,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.0127,"latestTime":"09-11 16:00:00 EDT","open":27.401,"high":27.5,"low":27.3696,"amount":32812,"amplitude":0.004767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.3569,"nav":27.337,"aum":2460334.39,"dividendRate":0.016467,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"volumeRatio":3.974015203722743},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.974015203722743,"shares":90001,"dividePrice":0.4507,"high":27.5,"amplitude":0.004767,"preClose":27.3569,"low":27.3696,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.3696,"eps":0,"divideRate":0.016467,"volume":1193,"delay":0,"ttmEps":0,"open":27.401,"prevYearClose":25,"prevWeekClose":28.8896,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":28.4889,"twentyDayClose":28.3265},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663404203","title":"Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103","url":"https://stock-news.laohu8.com/highlight/detail?id=2663404203","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663404203?lang=en_us&edition=fundamental","pubTime":"2026-08-31 03:35","pubTimestamp":1788118510,"startTime":"0","endTime":"0","summary":"Tenax Therapeutics (TENX) announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with pulmonary hyp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tenax-therapeutics-announces-results-from-phase-3-level-trial-of-tnx-103-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","TENX","MEDX","BK4539","LENZ","BK4139","IDNA","HYLG","GDOC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019703","title":"Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019703","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019703?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:52","pubTimestamp":1787964735,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an announcement. Takeda has secured U.S. FDA approval for MIMRYLO (rusfertide), a first-in-cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","MRNY","IEIH","RSPH","MRNX","BMED","LFSC","SYNB","TBXU","NVIB","FRTY","TECB","BK4588","PSCH","IBB","MEDI","BBP","PINK","BK4585","GNMX","LABU","GDOC","IYH","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016033","title":"Takeda receives FDA approval of NDA for Mimrylo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016033","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016033?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:00","pubTimestamp":1787958013,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia ve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","BBP","BK4007","IYH","NVIB","IDNA","IEIH","GNMX","TECB","MRNY","BK4588","PSCH","SYNB","PINK","IBB","LFSC","MRNX","TAK","TBXU","GDOC","BMED","XLVX","BK4585","LABU","MEDI","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663015241","title":"Health Care Down, but not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2663015241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663015241?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:22","pubTimestamp":1787952120,"startTime":"0","endTime":"0","summary":"Health-care companies fell, but not by as much as the broad market, as traders rotated into sectors less sensitive to interest-rate movements.BioNTech shares slid after the biotech firm scrapped a clinical trial for its mRNA cancer vaccine, marking the second setback this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XBI","BK4588","XLV","LABU","NVIB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705792","title":"Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705792","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662705792?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:22","pubTimestamp":1787898153,"startTime":"0","endTime":"0","summary":"Repligen recently reported past second-quarter 2026 results that exceeded earnings and revenue expectations and raised its full-year 2026 guidance, highlighting broad year-over-year growth across filtration, chromatography, proteins, and process analytics.\nAn interesting detail is that this operational momentum, accompanied by higher full-year forecasts and rising analyst estimates, may reinforce perceptions of Repligen’s business strength across multiple bioprocessing franchises.\nWe’ll now...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0205193047.USD","LU0205194284.USD","BK4121","NVIB","LU1815336091.USD","LU0012050646.USD","LU0757428866.USD","LU0106261612.USD","XBIX","RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662403754","title":"NeuroThera Labs Hires European IR Firm to Expand Investor Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2662403754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662403754?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:02","pubTimestamp":1787878968,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an announcement. NeuroThera Labs Inc., a clinical-stage biotech subsidiary of SciSparc Ltd. listed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","EPV","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662871430","title":"Oppenheimer biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662871430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662871430?lang=en_us&edition=fundamental","pubTime":"2026-08-28 02:00","pubTimestamp":1787853615,"startTime":"0","endTime":"0","summary":"Biotech Analysts, along with the Co-Director of Stanford Amyloid Cente, discuss the full results from AZN/IONS‘s CARDIO-TTRansform trial on an Anal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XBIX","BK4581","NVIB","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085942","title":"AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085942","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085942?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:01","pubTimestamp":1787835660,"startTime":"0","endTime":"0","summary":"Video webcast now availablehere OCALA, Fla., Aug.  27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)(“AIM” or the “Company”) today announced that it participated in the Virtual Inv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/27/3352073/29489/en/aim-immunotech-participates-in-the-virtual-investor-why-now-on-demand-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","MEDX","NVIB","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662470993","title":"Becton Dickinson announces STANCE clinical trial enrollment milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2662470993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662470993?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:55","pubTimestamp":1787828139,"startTime":"0","endTime":"0","summary":"Becton Dickinson (BDX) announced a milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial eval...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/becton-dickinson-announces-stance-clinical-trial-enrollment-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/becton-dickinson-announces-stance-clinical-trial-enrollment-milestone-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0162691827.USD","LU0130518102.USD","LU1854104046.USD","LU0985489474.SGD","LU0289739343.SGD","LU0072461881.USD","LU1201861165.SGD","LU0130103400.USD","HYLG","BK4588","LU0266013472.USD","BK4504","BK4585","LU1894683264.USD","LU0985320562.USD","GDOC","LU0477156797.USD","LU1150488135.SGD","LU1150488218.USD","LU0511384066.AUD","LU0648000940.SGD","LU1489326972.SGD","LU1894683348.USD","LU0433182093.SGD","LU0289961442.SGD","LU0006061336.USD","LU1854103824.USD","IHI","BK4082","LU0068578508.USD","LU1571399168.USD","NVIB","MEDX","IDNA","LU0878866978.SGD","BDX","LU1059921491.USD","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662221703","title":"Natera and Angiex partner in tumor testing using Signatera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662221703","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662221703?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:10","pubTimestamp":1787825446,"startTime":"0","endTime":"0","summary":"Natera (NTRA) announced a new Signatera collaboration with Angiex, a privately held biotech company developing a portfolio of Nuclear-Delivered Ant...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065170008.USD","LU1988902786.USD","HELX","LU2264538146.SGD","BK4139","LU2065731478.USD","LU0345770993.USD","LU2065171311.SGD","LU0012050646.USD","NVIB","LU0106261612.USD","NTRA","LU1064131342.USD","LU0963586101.USD","GNOM","LU2065171402.SGD","XBIX","LU0053671581.USD","LU2324357040.USD","LU0345770308.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662747010","title":"Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2662747010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662747010?lang=en_us&edition=fundamental","pubTime":"2026-08-27 05:47","pubTimestamp":1787780836,"startTime":"0","endTime":"0","summary":"Immatics ( ($IMTX) ) just unveiled an announcement. Immatics N.V., a Nasdaq-listed biotech company headquartered in Houston and Tübingen, focuses o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCLG","EQR","BK4215","XBIX","BK4588","REZ","BK4585","NVIB","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662874134","title":"Roche receives FDA approval for companion diagnostic tests for Ziihera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662874134","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662874134?lang=en_us&edition=fundamental","pubTime":"2026-08-27 03:00","pubTimestamp":1787770816,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that it has received FDA approval for expanded use of its PATHWAY HER2 and VENTANA HER2 Dual ISH DNA Probe Cocktail tests. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","GNMX","IBB","BK4007","FRTY","SYNB","MRNX","IEIH","BBP","TECB","GDOC","IDNA","IYH","BK4585","TBXU","HRTS","RSPH","LFSC","RHHBY","BK4588","BMED","XLVX","PINK","CANC","MRNY","PSCH","03165","LABU","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797746","title":"Revolution Medicines prices Rasonque at $39,800 for 30-day supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766320,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenoc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","IE0009354923.USD","IE00BJJMRZ35.SGD","TBXU","BBH","NVIB","PSCH","MRNX","BBP","TECB","BMED","BK4588","CANC","GNMX","RVMD","LABU","IBB","SYNB","LU0320765992.SGD","IE00B2B36J28.USD","BK4139","LU0109394709.USD","IE0002141913.USD","MRNY","RSPH","XLVX","IDNA","LU0889565916.HKD","BK4585","FRTY","PINK","GDOC","MEDI","IE00B4R5TH58.HKD","IE0009355771.USD","IYH","PTH","IE00BJT1NW94.SGD","IEIH","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662074659","title":"Revolution Medicines announces FDA approval of Rasonque in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662074659","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662074659?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:05","pubTimestamp":1787763925,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE once-daily oral tablets, for the treatment o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","IYH","GDOC","RVMD","MRNY","BBH","IE00BFTCPJ56.SGD","LFSC","BMED","IE00BJJMRZ35.SGD","MRNX","IE0002141913.USD","IE00B2B36J28.USD","BK4139","CANC","SYNB","RSPH","BBP","TBXU","IE00BJT1NW94.SGD","IDNA","BK4585","NVIB","BK4588","FRTY","XLVX","LABU","PSCH","TECB","LU0320765992.SGD","PINK","IE0009355771.USD","PTH","IBB","IEIH","MEDI","IE0009354923.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662714236","title":"IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2662714236","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662714236?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:30","pubTimestamp":1787747400,"startTime":"0","endTime":"0","summary":"Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones A patient treated with IMNN-001 will s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351335/0/en/imunon-to-host-2026-r-d-day-highlighting-phase-3-ovation-3-trial-and-the-clinical-potential-of-imnn-001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","BK4588","HST","BK4585","IMNN","NVIB","IDNA","GDOC","BK4181","BK4218","MEDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662471428","title":"Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662471428","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662471428?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:30","pubTimestamp":1787747400,"startTime":"0","endTime":"0","summary":"If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351327/0/en/celcuity-submits-snda-to-fda-for-revtorpyk-gedatolisib-for-hr-her2-pik3ca-mutant-locally-advanced-or-metastatic-breast-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","LU1878469433.USD","IE00B19Z4B17.USD","BK4225","LU2089985449.USD","NVIB","IE00B7SZL793.SGD","LU2931357623.SGD","IDNA","BK4203","HR","LU0274383776.USD","BK4588","SRET","HYLG","MEDX","AEIS","BK4157","BK4139","IE0031619046.USD","GDOC","BK4599","ALT","BK4585","LABU","LU0757428866.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760410","title":"4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760410","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760410?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:13","pubTimestamp":1787724830,"startTime":"0","endTime":"0","summary":"4basebio UK Societas ( ($GB:4BB) ) has issued an update. 4basebio PLC, a UK-listed biotech focused on synthetic, cell-free DNA and mRNA for advance...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VAQC","BK4561","DNA","BK4109","XBIX","BK4139","NVIB","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","LABU","GNMX","IYH","IEIH","ONC","BMED","TBXU","IDNA","PINK","NVIB","BK4585","BBP","RSPH","BK4588","LFSC","MRNX","GDOC","XLVX","BK4139","TECB","MEDI","SYNB","FRTY","MRNY","PSCH","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175807","title":"U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175807","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175807?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:23","pubTimestamp":1787667780,"startTime":"0","endTime":"0","summary":"Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-li","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350636/0/en/u-s-fda-approves-ziihera-zanidatamab-hrii-with-and-without-tislelizumab-plus-chemotherapy-in-first-line-her2-advanced-gastroesophageal-adenocarcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BFJL","DEFI","BTCW","BITI","DFII","NVIB","BITY","BTCO","EZBC","BTCL","BITX","GBTC","CBOA","YBTC","CRC","XBTY","MNRS","HODL","BITB","SBIT","IDNA","MAXI","CBXJ","IBIT","BFAP","CBOY","BTRN","AEIS","BITU","BMED","BPI","BTCC","CBTJ","BTC","CBXO","CBOJ","BRRR","CBXY","BTF","CBTA","CBTY","FBTC","BITO","ARKB","BTCZ","CBTO","GDOC","BTCI","BCCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732058","title":"Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732058?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:55","pubTimestamp":1787662500,"startTime":"0","endTime":"0","summary":"President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MEDX","BK4007","03160","NVIB","BK4555","BK4588","HYLG","BK4585","IDNA","BK4099","LABU","BK4604","TM","DARE","GDOC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":3,"totalSize":170,"code":"91000000","status":"200"}]}}